



2024-2025 ECCO Annual Disclosure of Potential Conflict of Interest

Name: Jairath, Vipul

In its aim to foster transparency and based on the ICJME Disclosure Form for Potential Conflict of Interest, ECCO has collected the according information of ECCO Officers and invited congress faculty at ECCO'25 via its online submission system.

The CoI Disclosure information is updated every autumn in line with the respective Congress business year. The purpose is to have a comprehensive declaration of interests for ECCO activities.

In case different disclosure answers have been submitted for different ECCO'25 presentations, the 2024-2025 ECCO Annual Disclosure of Potential Conflict of Interest on the association website shows the merged version of the answers to the following questions:

- Disclosure statement:
 - I have no potential conflict of interest to disclose
 - I have potential conflict of interest to disclose
- Potential Conflict of Interest can involve: grants, honoraria, shares, paid positions on advisory boards, etc.:
 - Grant
 - Personal Fees
 - Non-financial support
 - Other

Disclosures statement based on answers received:

Grant: |Celgene/BMS, Pfizer, Abbvie, Boehringer Ingelheim, Eli Lilly, Janssen, Takeda, Gilead Sciences, Tigenix| |Personal Fees: |AbbVie, Alimentiv Inc, Altrubio, Anokion, Amgen, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Avoro Capital, BioJamp, Blackbird Laboratories, Bristol Myers Squibb, Celltrion, Eli Lilly, Endpoint Health, Entera, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, Gilde Healthcare, GlaxoSmithKline, Genentech, Gilead, Innomar Strategies, Janssen, Knightslab, KSL Diagnostics, Merck, Metacrine, MRM Health, Mylan, Pandion, Pendopharm, Pfizer, Pioneering Medicine, Protagonist Therapeutics, Prometheus Biosciences, Reistone Biopharma, Roche, Roivant, Sandoz, SCOPE, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx Biosciences, Viatrix, Vividion